Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors

2019-10-10 09:39:37 | BioPortfolio


This study evaluates whether it is safe to Focused Ultrasound Ablation (FUSA) treatments with and without PD-1 blockade and with and without imiquimod. A device called the Echopulse will be used for the FUSA therapy. Patients will be assigned to 1 of 2 cohorts depending on their disease and treatment status. In Cohort 1, patients will receive FUSA therapy while receiving PD-1 blockade therapy as part of standard clinical care treatment. In Cohort 2, patients who discontinue or are ineligible for PD-1 blockade therapy will undergo FUSA without concurrent systemic therapy, with the goal of utilizing the FUSA to boost the innate immune response. The optional secondary regimen will combine FUSA (+/- PD-1 blockade) with imiquimod, which is a topical TLR7 agonist.

Study Design




Echopulse, Imiquimod, Standard of Care PD-1 Therapy


Not yet recruiting


University of Virginia

Results (where available)

View Results


Published on BioPortfolio: 2019-10-10T09:39:37-0400

Clinical Trials [2851 Associated Clinical Trials listed on BioPortfolio]

Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma

This pilot trial studies the side effects and how well imiquimod and pembrolizumab work in treating patients with stage IIIB-IV melanoma. Imiquimod may stimulate the immune system. Monoclo...

Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin

RATIONALE: Biological therapies, such as imiquimod, may stimulate the immune system in different ways and stop tumor cells from growing. Laser therapy uses light to kill tumor cells. Givin...

Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Biological therapies, such as imiquimod, may stimulate the immune system in...

NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)

This study evaluates a cancer vaccine in melanoma patients who have resected melanoma but are at high risk for recurrence (stages IIB-III). This is a single arm, open label, pilot/phase I ...

Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna

This is a prospective, longitudinal, uncontrolled study with follow-up for 5 years.Patients having undergone surgical excision of lentigo maligna (LM) or lentigo maligna melanoma (LMM) wil...

PubMed Articles [22699 Associated PubMed Articles listed on BioPortfolio]

Clinical usefulness of dermoscopy in the management of lentigo maligna melanoma treated with topical imiquimod: a case report.

The importance of dermoscopy for diagnosing lentigo maligna melanoma (LMM) is well known. More recently, dermoscopy has been proposed as a useful tool also for the treatment choice and monitoring. Her...

A distinct pre-treatment immune gene signature in lentigo maligna is associated with imiquimod response.

Lentigo Maligna (LM) is a common subtype of in-situ melanoma on chronically sun-exposed skin, particularly the head and neck of older patients. Whilst surgery is the standard treatment, there is assoc...

Targeted Therapy in Advanced Melanoma With Rare Mutations.

BRAF/MEK inhibition is a standard of care for patients with V600E/K-mutated metastatic melanoma. For patients with less frequent mutations, however, efficacy data are limited.

Heterogeneity of Melanoma with Stem Cell Properties.

Metastatic melanoma continues to present a significant challenge-with a cure rate of less than 10% and a median survival of 6-9 months. Despite noteworthy advances in the field, the heterogeneity of ...

Evolution of Excisional Surgery Practices for Melanoma in the United States.

National Comprehensive Cancer Network guidelines for melanoma have consistently recommended wide local excision as the standard of care since their inception. Although surgery with more comprehensive ...

Medical and Biotech [MESH] Definitions

An unpigmented malignant melanoma. It is an anaplastic melanoma consisting of cells derived from melanoblasts but not forming melanin. (Dorland, 27th ed; Stedman, 25th ed)

The minimum acceptable patient care, based on statutes, court decisions, policies, or professional guidelines.

Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA.

A process in which peripheral blood is exposed in an extracorporeal flow system to photoactivated 8-methoxypsoralen (METHOXSALEN) and ultraviolet light - a procedure known as PUVA THERAPY. Photopheresis is at present a standard therapy for advanced cutaneous T-cell lymphoma; it shows promise in the treatment of autoimmune diseases.

A cellular subtype of malignant melanoma. It is a pigmented lesion composed of melanocytes occurring on sun-exposed skin, usually the face and neck. The melanocytes are commonly multinucleated with a "starburst" appearance. It is considered by many to be the in situ phase of lentigo maligna melanoma.

More From BioPortfolio on "Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors"

Quick Search

Relevant Topics

Radiology is the branch of medicine that studies imaging of the body; X-ray (basic, angiography, barium swallows), ultrasound, MRI, CT and PET. These imaging techniques can be used to diagnose, but also to treat a range of conditions, by allowing visuali...

Skin cancers
There are three main types of skin cancer: basal cell carcinoma, squamous cell carcinoma and malignant melanoma. Basal cell carcinoma Basal cell carcinoma, or BCC, is a cancer of the basal cells at the bottom of the epidermis. It’s very common ...

Searches Linking to this Trial